Contraception
Volume 74, Issue 6 , Pages 439-445, December 2006

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results☆

Data contained in this report were presented at the annual meeting of the American Society for Reproductive Medicine, Montreal, Canada, October 2005.

  • David F. Archer

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 757 446 7444; fax: +1 757 446 8998.
    • ,
  • Jeffrey T. Jensen

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA
    • ,
  • Julia V. Johnson

      Affiliations

    • Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    • ,
  • Hannah Borisute

      Affiliations

    • Women's Health, Clinical Research/ Development, Wyeth Research, Collegeville, PA 19426, USA
    • ,
  • Gary S. Grubb

      Affiliations

    • Women's Health, Clinical Research/ Development, Wyeth Research, Collegeville, PA 19426, USA
    • ,
  • Ginger D. Constantine

      Affiliations

    • Women's Health, Clinical Research/ Development, Wyeth Research, Collegeville, PA 19426, USA

Received 30 March 2006; received in revised form 12 July 2006; accepted 12 July 2006. published online 20 September 2006.

Abstract 

Objective

This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 μg/ethinyl estradiol (EE) 20 μg (continuous LNG/EE).

Methods

Healthy women aged 18–49 years with regular menstrual cycles for 3 months enrolled in this single-treatment open-label study and took one pill of LNG 90 μg/EE 20 μg daily for 12 months.

Results

For the 2134 subjects enrolled, the Pearl Index method failure was 1.26, and user failure was 0.34. While on Pill Pack 13, 58.7% of subjects reported amenorrhea and 79.0% reported absence of bleeding. Overall, the number of bleeding and spotting days per pill pack declined progressively. Adverse events and discontinuations were comparable to those reported for cyclic oral contraceptive (OC) regimens, except for higher rates in those related to uterine bleeding.

Conclusions

Continuous LNG/EE demonstrated a good safety profile and efficacy similar to cyclic OCs. The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days.

Keywords: Continuous oral contraceptive, Levonorgestrel/ethinyl estradiol, Amenorrhea, Menses inhibition

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This study (ClinicalTrials.gov; NCT00245921) was supported by a grant from Wyeth Research (Collegeville, PA). Drs. David F. Archer, Jeffrey T. Jensen and Julia V. Johnson were investigators for this study and received research funding from Wyeth Research. Other sources of research funding and/or financial relationships include the following: Agile Therapeutics, Berlex, Genentech, Warner Chilcott, Lilly, Novo Nordisk, Ortho-McNeil, Organon International, Solvay Pharmaceuticals, Barr Laboratories, Duramed Pharmaceuticals, Johnson & Johnson and Wyeth for Dr. Archer; Berlex, Warner Chilcott, Pfizer, Organon International and Barr Laboratories for Dr. Jensen; and Berlex, Novo Nordisk, Pharmacia, Procter & Gamble for Dr. Johnson. Drs. Hannah Borisute, Gary S. Grubb and Ginger D. Constantine are employees of Wyeth Research. Other financial affiliations are Merck, Teva and Johnson & Johnson for Dr. Borisute; and Johnson & Johnson for Dr. Grubb. Dr. Constantine has no financial affiliations.

PII: S0010-7824(06)00310-6

doi:10.1016/j.contraception.2006.07.005

Contraception
Volume 74, Issue 6 , Pages 439-445, December 2006

Article Tools

* Image Usage & Resolution